<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276288</url>
  </required_header>
  <id_info>
    <org_study_id>1245.42</org_study_id>
    <secondary_id>2010-019624-31</secondary_id>
    <nct_id>NCT01276288</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes</brief_title>
  <official_title>Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the effect of BI 10773,
      hydrochlorothiazide and torasemide on changes in serum and urine electrolytes. Furthermore
      the pharmacodynamic and pharmacokinetic interactions between BI 10773 and diuretics should be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline</measure>
    <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in clearance of sodium, potassium, creatinine, magnesium, chloride,calcium, phosphate and uric acid from baseline, where baseline is defined as the value obtained from the last 24-h collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline</measure>
    <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in urinary excretion in a 24-hour period of sodium, potassium, magnesium, chloride, calcium, phosphate, creatinine, uric acid, glucose from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period. This applies also to sodium excretion in urine, which is additionally obtained one day before the drug administration before the second period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline</measure>
    <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in urinary excretion in a 24-hour period of N-terminal telopeptide (NTx) from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Osmolality From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Changes in serum osmolality from baseline based on a blood sample.
Baseline was defined as the measurement obtained before the first drug administration in the first period.
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of sodium, potassium, magnesium, calcium, chloride, phosphate, glucose and urea from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Creatinine and Uric Acid From Baseline</measure>
    <time_frame>baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of Creatinine and Uric acid from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of ALP from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of Renin, intact parathyroid hormone (iPTH) and 1,25-dihydroxyvitamin D from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Aldosterone From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of Aldosterone from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in serum concentration of fibroblast growth factor-23 (FGF- 23) from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline, The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urea Concentration in Urine</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in urea concentration in urine from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine pH From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in urine pH from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Osmolality From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in urine osmolality from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Changes in bicarbonate concentrations of calcium, bicarbonate ions and base excess in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pH in Capillary or Arterialised Blood From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in pH in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Weight From Baseline</measure>
    <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change in body weight from baseline , where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary Weight From Baseline</measure>
    <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
    <description>Change from baseline in urinary weight in a 24 hour (h)- collection period, where baseline is the last 24-h collection period before first trial drug administration in each treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Micturition Frequency From the Baseline</measure>
    <time_frame>Baseline and day 5</time_frame>
    <description>For this endpoint the change in total micturition frequency from the baseline was only examined for EMPA where baseline was defined as the day before the first drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment</measure>
    <time_frame>One day before the drug administration, then day 4 after the first drug administration</time_frame>
    <description>The change in total Muscle sympathetic nerve activity (MSNA) that represents an area under the curve of all C-fiber action potentials per minute. This endpoint was evaluated only for Empa. For this endpoint a baseline value was not defined. However, the parameters obtained at 2 measurements time points during the trial were compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Sodium Excretion Over 24-hour run-in Periods</measure>
    <time_frame>Day 3, 2 and 1 before the first drug administration</time_frame>
    <description>Urinary sodium excretion over 24-hour run-in periods to assess the harmonisation of electrolytes after intake of a standardised diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 &amp; 8 with EMPA plus diuretic</time_frame>
    <description>Area under the concentration-time curve of Empa in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration of Empa in Plasma (Cmax, ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 &amp; 8 with EMPA plus diuretic</time_frame>
    <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 &amp; 8 with EMPA plus HCT</time_frame>
    <description>Area under the concentration-time curve of HCT in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration of HCT in Plasma (Cmax, ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 &amp; 8 with EMPA plus HCT</time_frame>
    <description>Maximum measured concentration of HCT in plasma (Cmax, ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 &amp; 8 with EMPA plus TOR</time_frame>
    <description>Area under the concentration-time curve of TOR in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration of TOR in Plasma (Cmax, ss)</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 &amp; 8 with EMPA plus TOR</time_frame>
    <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator</measure>
    <time_frame>From first drug administration until up to 14 days after the last drug administration, up to 35 days</time_frame>
    <description>Number of subjects with clinical relevant abnormalities in vital signs (blood pressure, pulse rate), 12-lead resting electrocardiogram (ECG), clinical laboratory tests (haematology, clinical chemistry, urinalysis, and monitoring of fasting plasma glucose), physical examination and assessment of tolerability by the investigator.
New abnormal findings were reported as Adverse Events (AE). Only Alanine aminotransferase normal under system organ class investigations was determined as an existing AE.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of BI 10773 once daily for 5 days (20 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of torasemide (TOR) once daily for 4 days (10 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of BI 10773 + HTC once daily for 5 days (10 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of BI 10773 + TOR once daily for 5 days (10 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>torasemide</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Reference 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Reference 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>torasemide</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>multiple oral doses</description>
    <arm_group_label>Reference 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. male and female patients of type 2 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.42.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2014</results_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, open-label, 2- way cross-over study. All patients received empagliflozin (EMPA). After 7days washout period, half of patients received hydrochlorothiazide (HCT), other half torasemide (TOR) on its own or with EMPA. Then HCT or TOR and its combination with EMPA were administered first, followed by EMPA after 7 days washout.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empa / Empa+HCT</title>
          <description>Patients received 25mg empagliflozin (Empa) orally in a form of a film-coated tablet once daily following an overnight fast of at least 10 hours (h). Following a wash-out period of seven days, 25mg hydrochlorothiazide (HCT) in a form of a film-coated tablet was administered orally once daily in combination with 25mg Empa.</description>
        </group>
        <group group_id="P2">
          <title>Empa+HCT/ Empa</title>
          <description>Patients received 25mg hydrochlorothiazide (HCT) in a form of a film-coated tablet orally once daily in combination with 25mg Empa. Following a wash-out period of seven days 25 mg Empa was administered in a form of a film-coated tablet orally once daily following an overnight fast of at least 10 hours (h).</description>
        </group>
        <group group_id="P3">
          <title>Empa/ Empa+ TOR</title>
          <description>Patients received 25mg Empa in a form of a film-coated tablet orally once daily following an overnight fast of at least 10 hours (h). Following a wash-out period of seven days, 5 mg torasemide (TOR) in combination with 25mg Empa was administered.</description>
        </group>
        <group group_id="P4">
          <title>Empa+TOR/ Empa</title>
          <description>Patients received 5mg torasemide (TOR) in combination with 25mg Empa. Following a wash-out period of seven days, 25 mg Empa was administered in a form of a film-coated tablet orally once daily following an overnight fast of at least 10 hours (h).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received EMPA</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received EMPA+HCT</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received EMPA+TOR</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS) that includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Patients</title>
          <description>A randomised, open-label, multiple-dose, 2- way cross-over study. All patients received 25 mg empagliflozin in a form of a film-coated tablet orally once daily following an overnight fast of at least 10 hours (h) (days 1 to 5). Following a wash-out period of seven days, half of the patients received 25 mg hydrochlorothiazide (HCT) either on its own in a form of a film-coated tablet orally once daily (days 1 to 4) or in combination with 25 mg empagliflozin ( days 5 to 9), while the other half of the patients received 5 mg torasemide (TOR) either on its own (days 1 to 4) or in combination with the 25 mg empagliflozin ( days 5 to 9). This sequence was then reversed so that the HCT or TOR and its combination with 25 mg empagliflozin were administered first in a same manner as stated above, followed by 25 mg empagliflozin after seven days wash out period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline</title>
        <description>Change in clearance of sodium, potassium, creatinine, magnesium, chloride,calcium, phosphate and uric acid from baseline, where baseline is defined as the value obtained from the last 24-h collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
        <population>Pharmacodynamic (PD) analysis set completers includes all evaluable patients of the treated set who provide a baseline and at least one on-treatment observation for at least one primary (PD) endpoint under any treatment without important protocol violations relevant to the evaluation of PD and who continued the trial as planned</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline</title>
          <description>Change in clearance of sodium, potassium, creatinine, magnesium, chloride,calcium, phosphate and uric acid from baseline, where baseline is defined as the value obtained from the last 24-h collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>Pharmacodynamic (PD) analysis set completers includes all evaluable patients of the treated set who provide a baseline and at least one on-treatment observation for at least one primary (PD) endpoint under any treatment without important protocol violations relevant to the evaluation of PD and who continued the trial as planned</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.038"/>
                    <measurement group_id="O2" value="-0.055" spread="0.044"/>
                    <measurement group_id="O3" value="-0.071" spread="0.083"/>
                    <measurement group_id="O4" value="0.143" spread="0.036"/>
                    <measurement group_id="O5" value="-0.004" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.129" spread="0.042"/>
                    <measurement group_id="O2" value="-0.058" spread="0.056"/>
                    <measurement group_id="O3" value="-0.157" spread="0.064"/>
                    <measurement group_id="O4" value="0.114" spread="0.044"/>
                    <measurement group_id="O5" value="-0.117" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.040" spread="0.492"/>
                    <measurement group_id="O2" value="2.205" spread="0.539"/>
                    <measurement group_id="O3" value="-0.518" spread="0.585"/>
                    <measurement group_id="O4" value="4.125" spread="0.634"/>
                    <measurement group_id="O5" value="2.324" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.398" spread="0.171"/>
                    <measurement group_id="O2" value="1.826" spread="0.288"/>
                    <measurement group_id="O3" value="1.148" spread="0.206"/>
                    <measurement group_id="O4" value="1.115" spread="0.181"/>
                    <measurement group_id="O5" value="0.209" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.326" spread="0.087"/>
                    <measurement group_id="O2" value="-0.299" spread="0.094"/>
                    <measurement group_id="O3" value="-0.065" spread="0.108"/>
                    <measurement group_id="O4" value="-0.407" spread="0.102"/>
                    <measurement group_id="O5" value="-0.174" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.275" spread="0.842"/>
                    <measurement group_id="O2" value="4.633" spread="1.342"/>
                    <measurement group_id="O3" value="4.368" spread="1.342"/>
                    <measurement group_id="O4" value="2.795" spread="1.382"/>
                    <measurement group_id="O5" value="2.359" spread="1.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.377" spread="1.100"/>
                    <measurement group_id="O2" value="-0.476" spread="0.637"/>
                    <measurement group_id="O3" value="-1.310" spread="0.924"/>
                    <measurement group_id="O4" value="5.065" spread="1.376"/>
                    <measurement group_id="O5" value="4.359" spread="1.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.167" spread="4.306"/>
                    <measurement group_id="O2" value="-7.034" spread="5.494"/>
                    <measurement group_id="O3" value="-4.250" spread="6.574"/>
                    <measurement group_id="O4" value="-10.126" spread="7.989"/>
                    <measurement group_id="O5" value="-11.768" spread="7.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline</title>
        <description>Change in urinary excretion in a 24-hour period of sodium, potassium, magnesium, chloride, calcium, phosphate, creatinine, uric acid, glucose from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period. This applies also to sodium excretion in urine, which is additionally obtained one day before the drug administration before the second period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline</title>
          <description>Change in urinary excretion in a 24-hour period of sodium, potassium, magnesium, chloride, calcium, phosphate, creatinine, uric acid, glucose from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period. This applies also to sodium excretion in urine, which is additionally obtained one day before the drug administration before the second period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.300" spread="7.777"/>
                    <measurement group_id="O2" value="-11.700" spread="8.495"/>
                    <measurement group_id="O3" value="-13.700" spread="16.445"/>
                    <measurement group_id="O4" value="28.900" spread="7.512"/>
                    <measurement group_id="O5" value="1.200" spread="17.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.300" spread="6.363"/>
                    <measurement group_id="O2" value="-12.300" spread="7.939"/>
                    <measurement group_id="O3" value="-22.000" spread="9.421"/>
                    <measurement group_id="O4" value="11.400" spread="6.092"/>
                    <measurement group_id="O5" value="-14.600" spread="12.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.370" spread="3.171"/>
                    <measurement group_id="O2" value="6.200" spread="3.008"/>
                    <measurement group_id="O3" value="-6.990" spread="3.920"/>
                    <measurement group_id="O4" value="15.790" spread="2.963"/>
                    <measurement group_id="O5" value="8.460" spread="5.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.190" spread="0.236"/>
                    <measurement group_id="O2" value="2.270" spread="0.387"/>
                    <measurement group_id="O3" value="1.720" spread="0.263"/>
                    <measurement group_id="O4" value="2.030" spread="0.225"/>
                    <measurement group_id="O5" value="1.050" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.160" spread="0.281"/>
                    <measurement group_id="O2" value="-1.020" spread="0.299"/>
                    <measurement group_id="O3" value="-0.430" spread="0.377"/>
                    <measurement group_id="O4" value="-1.360" spread="0.294"/>
                    <measurement group_id="O5" value="-0.740" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.250" spread="1.198"/>
                    <measurement group_id="O2" value="9.000" spread="2.261"/>
                    <measurement group_id="O3" value="4.900" spread="1.900"/>
                    <measurement group_id="O4" value="8.300" spread="2.103"/>
                    <measurement group_id="O5" value="5.000" spread="2.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.043"/>
                    <measurement group_id="O2" value="-0.078" spread="0.058"/>
                    <measurement group_id="O3" value="-0.073" spread="0.045"/>
                    <measurement group_id="O4" value="0.022" spread="0.041"/>
                    <measurement group_id="O5" value="-0.040" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.641" spread="0.334"/>
                    <measurement group_id="O2" value="-0.037" spread="0.251"/>
                    <measurement group_id="O3" value="-0.500" spread="0.349"/>
                    <measurement group_id="O4" value="1.555" spread="0.327"/>
                    <measurement group_id="O5" value="1.244" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.449" spread="60.015"/>
                    <measurement group_id="O2" value="17.584" spread="8.161"/>
                    <measurement group_id="O3" value="17.932" spread="25.477"/>
                    <measurement group_id="O4" value="685.233" spread="68.035"/>
                    <measurement group_id="O5" value="740.910" spread="54.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline</title>
        <description>Change in urinary excretion in a 24-hour period of N-terminal telopeptide (NTx) from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline</title>
          <description>Change in urinary excretion in a 24-hour period of N-terminal telopeptide (NTx) from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>nM BCE/ mMC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.010" spread="1.334"/>
                    <measurement group_id="O2" value="0.730" spread="2.704"/>
                    <measurement group_id="O3" value="2.030" spread="0.723"/>
                    <measurement group_id="O4" value="1.380" spread="3.429"/>
                    <measurement group_id="O5" value="3.900" spread="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Osmolality From Baseline</title>
        <description>Changes in serum osmolality from baseline based on a blood sample.
Baseline was defined as the measurement obtained before the first drug administration in the first period.
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Osmolality From Baseline</title>
          <description>Changes in serum osmolality from baseline based on a blood sample.
Baseline was defined as the measurement obtained before the first drug administration in the first period.
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mOsm/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.950" spread="3.748"/>
                    <measurement group_id="O2" value="-7.500" spread="3.519"/>
                    <measurement group_id="O3" value="-5.500" spread="2.915"/>
                    <measurement group_id="O4" value="-2.200" spread="3.972"/>
                    <measurement group_id="O5" value="10.500" spread="3.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline</title>
        <description>Change in serum concentration of sodium, potassium, magnesium, calcium, chloride, phosphate, glucose and urea from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline</title>
          <description>Change in serum concentration of sodium, potassium, magnesium, calcium, chloride, phosphate, glucose and urea from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" spread="0.447"/>
                    <measurement group_id="O2" value="-0.500" spread="0.401"/>
                    <measurement group_id="O3" value="0.200" spread="0.573"/>
                    <measurement group_id="O4" value="-0.100" spread="0.433"/>
                    <measurement group_id="O5" value="1.600" spread="1.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.170" spread="0.107"/>
                    <measurement group_id="O2" value="-0.470" spread="0.087"/>
                    <measurement group_id="O3" value="-0.200" spread="0.087"/>
                    <measurement group_id="O4" value="-0.530" spread="0.091"/>
                    <measurement group_id="O5" value="-0.360" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" spread="0.011"/>
                    <measurement group_id="O2" value="0.025" spread="0.014"/>
                    <measurement group_id="O3" value="0.059" spread="0.010"/>
                    <measurement group_id="O4" value="0.130" spread="0.014"/>
                    <measurement group_id="O5" value="0.145" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.050" spread="0.592"/>
                    <measurement group_id="O2" value="-2.600" spread="0.521"/>
                    <measurement group_id="O3" value="1.000" spread="0.775"/>
                    <measurement group_id="O4" value="-3.200" spread="1.365"/>
                    <measurement group_id="O5" value="2.100" spread="1.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.023"/>
                    <measurement group_id="O2" value="-0.040" spread="0.034"/>
                    <measurement group_id="O3" value="-0.080" spread="0.020"/>
                    <measurement group_id="O4" value="-0.010" spread="0.031"/>
                    <measurement group_id="O5" value="-0.060" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.031"/>
                    <measurement group_id="O2" value="0.060" spread="0.031"/>
                    <measurement group_id="O3" value="-0.060" spread="0.034"/>
                    <measurement group_id="O4" value="0.170" spread="0.040"/>
                    <measurement group_id="O5" value="0.050" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.710" spread="0.153"/>
                    <measurement group_id="O2" value="0.650" spread="0.149"/>
                    <measurement group_id="O3" value="0.318" spread="0.220"/>
                    <measurement group_id="O4" value="1.504" spread="0.161"/>
                    <measurement group_id="O5" value="2.122" spread="0.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.123" spread="0.250"/>
                    <measurement group_id="O2" value="0.849" spread="0.177"/>
                    <measurement group_id="O3" value="0.527" spread="0.290"/>
                    <measurement group_id="O4" value="-0.033" spread="0.168"/>
                    <measurement group_id="O5" value="-0.526" spread="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Creatinine and Uric Acid From Baseline</title>
        <description>Change in serum concentration of Creatinine and Uric acid from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Creatinine and Uric Acid From Baseline</title>
          <description>Change in serum concentration of Creatinine and Uric acid from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.175" spread="1.585"/>
                    <measurement group_id="O2" value="-0.340" spread="1.441"/>
                    <measurement group_id="O3" value="-2.180" spread="1.811"/>
                    <measurement group_id="O4" value="6.280" spread="2.764"/>
                    <measurement group_id="O5" value="3.570" spread="2.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.950" spread="24.763"/>
                    <measurement group_id="O2" value="24.200" spread="9.087"/>
                    <measurement group_id="O3" value="-4.700" spread="9.164"/>
                    <measurement group_id="O4" value="-31.000" spread="18.582"/>
                    <measurement group_id="O5" value="-48.200" spread="12.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline</title>
        <description>Change in serum concentration of ALP from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline</title>
          <description>Change in serum concentration of ALP from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.750" spread="0.878"/>
                    <measurement group_id="O2" value="3.000" spread="1.274"/>
                    <measurement group_id="O3" value="2.400" spread="0.859"/>
                    <measurement group_id="O4" value="6.500" spread="1.515"/>
                    <measurement group_id="O5" value="5.800" spread="1.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline</title>
        <description>Change in serum concentration of Renin, intact parathyroid hormone (iPTH) and 1,25-dihydroxyvitamin D from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline</title>
          <description>Change in serum concentration of Renin, intact parathyroid hormone (iPTH) and 1,25-dihydroxyvitamin D from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Renin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.960" spread="4.155"/>
                    <measurement group_id="O2" value="16.150" spread="8.276"/>
                    <measurement group_id="O3" value="2.550" spread="1.882"/>
                    <measurement group_id="O4" value="32.760" spread="16.863"/>
                    <measurement group_id="O5" value="17.050" spread="3.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iPTH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.265" spread="1.593"/>
                    <measurement group_id="O2" value="6.160" spread="1.880"/>
                    <measurement group_id="O3" value="6.910" spread="2.059"/>
                    <measurement group_id="O4" value="9.280" spread="1.619"/>
                    <measurement group_id="O5" value="12.190" spread="3.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,25-dihydroxyvitamin D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" spread="3.488"/>
                    <measurement group_id="O2" value="1.560" spread="4.029"/>
                    <measurement group_id="O3" value="3.530" spread="5.123"/>
                    <measurement group_id="O4" value="-5.060" spread="4.070"/>
                    <measurement group_id="O5" value="-0.970" spread="4.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Aldosterone From Baseline</title>
        <description>Change in serum concentration of Aldosterone from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Aldosterone From Baseline</title>
          <description>Change in serum concentration of Aldosterone from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.020"/>
                    <measurement group_id="O2" value="0.099" spread="0.056"/>
                    <measurement group_id="O3" value="0.023" spread="0.018"/>
                    <measurement group_id="O4" value="0.124" spread="0.068"/>
                    <measurement group_id="O5" value="0.123" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline</title>
        <description>Change in serum concentration of fibroblast growth factor-23 (FGF- 23) from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline, The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline</title>
          <description>Change in serum concentration of fibroblast growth factor-23 (FGF- 23) from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline, The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>RU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.305" spread="23.759"/>
                    <measurement group_id="O2" value="29.050" spread="25.952"/>
                    <measurement group_id="O3" value="-0.680" spread="5.465"/>
                    <measurement group_id="O4" value="109.860" spread="53.745"/>
                    <measurement group_id="O5" value="13.820" spread="4.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urea Concentration in Urine</title>
        <description>Change in urea concentration in urine from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urea Concentration in Urine</title>
          <description>Change in urea concentration in urine from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.515" spread="14.048"/>
                    <measurement group_id="O2" value="67.570" spread="29.271"/>
                    <measurement group_id="O3" value="35.710" spread="34.666"/>
                    <measurement group_id="O4" value="11.780" spread="9.819"/>
                    <measurement group_id="O5" value="48.690" spread="31.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine pH From Baseline</title>
        <description>Change in urine pH from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine pH From Baseline</title>
          <description>Change in urine pH from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.132" spread="0.161"/>
                    <measurement group_id="O2" value="-0.452" spread="0.291"/>
                    <measurement group_id="O3" value="-0.147" spread="0.062"/>
                    <measurement group_id="O4" value="-0.448" spread="0.259"/>
                    <measurement group_id="O5" value="0.130" spread="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine Osmolality From Baseline</title>
        <description>Change in urine osmolality from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Osmolality From Baseline</title>
          <description>Change in urine osmolality from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mOsm/kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.15" spread="34.850"/>
                    <measurement group_id="O2" value="-3.900" spread="43.239"/>
                    <measurement group_id="O3" value="-5.800" spread="54.743"/>
                    <measurement group_id="O4" value="217.700" spread="31.430"/>
                    <measurement group_id="O5" value="330.400" spread="45.645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline</title>
        <description>Changes in bicarbonate concentrations of calcium, bicarbonate ions and base excess in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline</title>
          <description>Changes in bicarbonate concentrations of calcium, bicarbonate ions and base excess in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>mmol/ L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bicarbonate concentrations of calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.090" spread="0.309"/>
                    <measurement group_id="O2" value="2.020" spread="0.397"/>
                    <measurement group_id="O3" value="-0.400" spread="0.450"/>
                    <measurement group_id="O4" value="1.860" spread="0.445"/>
                    <measurement group_id="O5" value="-1.590" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bicarbonate ions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.012"/>
                    <measurement group_id="O2" value="-0.043" spread="0.023"/>
                    <measurement group_id="O3" value="-0.041" spread="0.018"/>
                    <measurement group_id="O4" value="-0.053" spread="0.015"/>
                    <measurement group_id="O5" value="-0.049" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Base excess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.045" spread="0.284"/>
                    <measurement group_id="O2" value="1.640" spread="0.325"/>
                    <measurement group_id="O3" value="-0.420" spread="0.386"/>
                    <measurement group_id="O4" value="1.720" spread="0.432"/>
                    <measurement group_id="O5" value="-1.450" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in pH in Capillary or Arterialised Blood From Baseline</title>
        <description>Change in pH in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in pH in Capillary or Arterialised Blood From Baseline</title>
          <description>Change in pH in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.004"/>
                    <measurement group_id="O2" value="0.003" spread="0.007"/>
                    <measurement group_id="O3" value="-0.002" spread="0.006"/>
                    <measurement group_id="O4" value="0.008" spread="0.008"/>
                    <measurement group_id="O5" value="-0.005" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight From Baseline</title>
        <description>Change in body weight from baseline , where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline</title>
          <description>Change in body weight from baseline , where baseline was defined as the last measurement before trial drug administration of each treatment period
The mean change from baseline was evaluated as:
Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.365" spread="0.535"/>
                    <measurement group_id="O2" value="-1.040" spread="0.227"/>
                    <measurement group_id="O3" value="-0.380" spread="0.149"/>
                    <measurement group_id="O4" value="-2.030" spread="0.344"/>
                    <measurement group_id="O5" value="-1.750" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Weight From Baseline</title>
        <description>Change from baseline in urinary weight in a 24 hour (h)- collection period, where baseline is the last 24-h collection period before first trial drug administration in each treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
        <time_frame>24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Weight From Baseline</title>
          <description>Change from baseline in urinary weight in a 24 hour (h)- collection period, where baseline is the last 24-h collection period before first trial drug administration in each treatment period.
The mean change from baseline was evaluated as:
Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,
The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa</description>
          <population>PD analysis set completers</population>
          <units>g/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.700" spread="95.358"/>
                    <measurement group_id="O2" value="-55.300" spread="67.517"/>
                    <measurement group_id="O3" value="-39.000" spread="106.642"/>
                    <measurement group_id="O4" value="429.000" spread="92.357"/>
                    <measurement group_id="O5" value="353.200" spread="116.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Micturition Frequency From the Baseline</title>
        <description>For this endpoint the change in total micturition frequency from the baseline was only examined for EMPA where baseline was defined as the day before the first drug administration.</description>
        <time_frame>Baseline and day 5</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Micturition Frequency From the Baseline</title>
          <description>For this endpoint the change in total micturition frequency from the baseline was only examined for EMPA where baseline was defined as the day before the first drug administration.</description>
          <population>PD analysis set completers</population>
          <units>voids per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.600" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment</title>
        <description>The change in total Muscle sympathetic nerve activity (MSNA) that represents an area under the curve of all C-fiber action potentials per minute. This endpoint was evaluated only for Empa. For this endpoint a baseline value was not defined. However, the parameters obtained at 2 measurements time points during the trial were compared.</description>
        <time_frame>One day before the drug administration, then day 4 after the first drug administration</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment</title>
          <description>The change in total Muscle sympathetic nerve activity (MSNA) that represents an area under the curve of all C-fiber action potentials per minute. This endpoint was evaluated only for Empa. For this endpoint a baseline value was not defined. However, the parameters obtained at 2 measurements time points during the trial were compared.</description>
          <population>PD analysis set completers</population>
          <units>action potentials per min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.241" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of Empa in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 &amp; 8 with EMPA plus diuretic</time_frame>
        <population>Pharmacokinetic (PK) set, including all patients of the treated set who provide at least one observation for at least one secondary PK endpoint of AUC τ,ss or C max,ss for any analyte under any treatment without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of Empa in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
          <population>Pharmacokinetic (PK) set, including all patients of the treated set who provide at least one observation for at least one secondary PK endpoint of AUC τ,ss or C max,ss for any analyte under any treatment without important protocol violations relevant to the evaluation of PK.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4990" spread="21.1"/>
                    <measurement group_id="O2" value="5570" spread="25.2"/>
                    <measurement group_id="O3" value="5260" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+HCT were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0092</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa plus HCT divided by Empa</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for sequence, period and treatment as fixed effects while subjects within sequences as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>107.08</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.11</ci_lower_limit>
            <ci_upper_limit>118.07</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0030</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa plus TOR divided by Empa</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for sequence, period and treatment as fixed effects while subjects within sequences as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>107.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.14</ci_lower_limit>
            <ci_upper_limit>116.11</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration of Empa in Plasma (Cmax, ss)</title>
        <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 &amp; 8 with EMPA plus diuretic</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of Empa in Plasma (Cmax, ss)</title>
          <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
          <population>PK set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="939" spread="21.4"/>
                    <measurement group_id="O2" value="1030" spread="31.2"/>
                    <measurement group_id="O3" value="949" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+HCT were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0199</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ HCT divided by Empa</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for sequence, period and treatment as fixed effects while subjects within sequences as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>18.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.55</ci_lower_limit>
            <ci_upper_limit>119.29</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0086</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR divided by Empa</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for sequence, period and treatment as fixed effects while subjects within sequences as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>107.50</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.90</ci_lower_limit>
            <ci_upper_limit>118.04</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of HCT in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 &amp; 8 with EMPA plus HCT</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O2">
            <title>HCT+ Empa</title>
            <description>Hydrochlorothiazide (HCT) 25 mg followed by Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of HCT in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
          <population>PK set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1040" spread="17.9"/>
                    <measurement group_id="O2" value="1000" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+HCT were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0008</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa plus HCT divided by HCT</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.08</ci_lower_limit>
            <ci_upper_limit>104.05</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration of HCT in Plasma (Cmax, ss)</title>
        <description>Maximum measured concentration of HCT in plasma (Cmax, ss) at steady state</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 &amp; 8 with EMPA plus HCT</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O2">
            <title>HCT+ Empa</title>
            <description>Hydrochlorothiazide (HCT) 25 mg followed by Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of HCT in Plasma (Cmax, ss)</title>
          <description>Maximum measured concentration of HCT in plasma (Cmax, ss) at steady state</description>
          <population>PK set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" spread="31.5"/>
                    <measurement group_id="O2" value="205" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+HCT were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0114</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ HCT divided by HCT</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>101.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.63</ci_lower_limit>
            <ci_upper_limit>116.85</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of TOR in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 &amp; 8 with EMPA plus TOR</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O2">
            <title>TOR+ Empa</title>
            <description>Torasemide (TOR) 5 mg and Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>TOR Metabolite (TOR-M1)</title>
            <description>TOR metabolite with one-tenth of pharmacological activity of TOR after TOR undergoes extensive hepatic metabolism.</description>
          </group>
          <group group_id="O4">
            <title>TOR Metabolite (TOR-M3)</title>
            <description>TOR metabolite which pharmacological activity is equal to TOR after TOR undergoes extensive hepatic metabolism.</description>
          </group>
          <group group_id="O5">
            <title>TOR-M1+ Empa</title>
            <description>TOR metabolite with one-tenth of pharmacological activity of TOR after TOR undergoes extensive hepatic metabolism in combination with Empa 25 mg</description>
          </group>
          <group group_id="O6">
            <title>TOR-M3 + Empa</title>
            <description>TOR metabolite which pharmacological activity is equal to TOR after TOR undergoes extensive hepatic metabolism in combination with Empa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of TOR in plasma at steady state over a uniform dosing interval τ (AUCτ,ss).</description>
          <population>PK set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1320" spread="14.0"/>
                    <measurement group_id="O2" value="1340" spread="16.1"/>
                    <measurement group_id="O3" value="74.8" spread="15.9"/>
                    <measurement group_id="O4" value="40.5" spread="23.9"/>
                    <measurement group_id="O5" value="78.1" spread="17.7"/>
                    <measurement group_id="O6" value="41.8" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa plus TOR divided by TOR</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>101.44</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.06</ci_lower_limit>
            <ci_upper_limit>103.88</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR-M1 divided by TOR-M1</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.42</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.39</ci_lower_limit>
            <ci_upper_limit>108.62</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0005</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR-M3 divided by TOR-M3</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.19</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.93</ci_lower_limit>
            <ci_upper_limit>111.01</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration of TOR in Plasma (Cmax, ss)</title>
        <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 &amp; 8 with EMPA plus TOR</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O2">
            <title>TOR+ Empa</title>
            <description>Torasemide (TOR) 5 mg and Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>TOR Metabolite (TOR-M1)</title>
            <description>TOR metabolite with one-tenth of pharmacological activity of TOR after TOR undergoes extensive hepatic metabolism.</description>
          </group>
          <group group_id="O4">
            <title>TOR Metabolite (TOR-M3)</title>
            <description>TOR metabolite which pharmacological activity is equal to TOR after TOR undergoes extensive hepatic metabolism.</description>
          </group>
          <group group_id="O5">
            <title>TOR-M1+ Empa</title>
            <description>TOR metabolite with one-tenth of pharmacological activity of TOR after TOR undergoes extensive hepatic metabolism in combination with Empa 25 mg</description>
          </group>
          <group group_id="O6">
            <title>TOR-M3 + Empa</title>
            <description>TOR metabolite which pharmacological activity is equal to TOR after TOR undergoes extensive hepatic metabolism in combination with Empa 25 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of TOR in Plasma (Cmax, ss)</title>
          <description>Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state</description>
          <population>PK set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710" spread="19.1"/>
                    <measurement group_id="O2" value="741" spread="12.9"/>
                    <measurement group_id="O3" value="42.6" spread="23.0"/>
                    <measurement group_id="O4" value="8.58" spread="12.3"/>
                    <measurement group_id="O5" value="43.8" spread="18.0"/>
                    <measurement group_id="O6" value="8.79" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0066</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR divided by TOR</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.81</ci_lower_limit>
            <ci_upper_limit>116.25</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>0.0012</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR-M1 divided by TOR-M1</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.67</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.13</ci_lower_limit>
            <ci_upper_limit>111.97</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Only patients in sequences Empa/Empa+TOR were included</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing in a confirmatory sense</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for ratio outside interval 80-125%
Ratio calculated as Empa+ TOR-M3 divided by TOR-M3</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model was adjusted for treatment as fixed effect and subject as random effect</method_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.42</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.65</ci_lower_limit>
            <ci_upper_limit>107.42</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV) reflecting intra-subject variabilities</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Sodium Excretion Over 24-hour run-in Periods</title>
        <description>Urinary sodium excretion over 24-hour run-in periods to assess the harmonisation of electrolytes after intake of a standardised diet</description>
        <time_frame>Day 3, 2 and 1 before the first drug administration</time_frame>
        <population>PD analysis set completers</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Sodium Excretion Over 24-hour run-in Periods</title>
          <description>Urinary sodium excretion over 24-hour run-in periods to assess the harmonisation of electrolytes after intake of a standardised diet</description>
          <population>PD analysis set completers</population>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 days before the drug administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.50" spread="20.30"/>
                    <measurement group_id="O2" value="211.10" spread="9.37"/>
                    <measurement group_id="O3" value="217.90" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 days before the drug administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.35" spread="10.26"/>
                    <measurement group_id="O2" value="183.30" spread="13.15"/>
                    <measurement group_id="O3" value="178.70" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 day before the drug administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.90" spread="8.57"/>
                    <measurement group_id="O2" value="170.10" spread="7.58"/>
                    <measurement group_id="O3" value="179.10" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator</title>
        <description>Number of subjects with clinical relevant abnormalities in vital signs (blood pressure, pulse rate), 12-lead resting electrocardiogram (ECG), clinical laboratory tests (haematology, clinical chemistry, urinalysis, and monitoring of fasting plasma glucose), physical examination and assessment of tolerability by the investigator.
New abnormal findings were reported as Adverse Events (AE). Only Alanine aminotransferase normal under system organ class investigations was determined as an existing AE.</description>
        <time_frame>From first drug administration until up to 14 days after the last drug administration, up to 35 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin (Empa)</title>
            <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide (HCT)</title>
            <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O3">
            <title>Torasemide (TOR)</title>
            <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Empa+ HCT</title>
            <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Empa + TOR</title>
            <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator</title>
          <description>Number of subjects with clinical relevant abnormalities in vital signs (blood pressure, pulse rate), 12-lead resting electrocardiogram (ECG), clinical laboratory tests (haematology, clinical chemistry, urinalysis, and monitoring of fasting plasma glucose), physical examination and assessment of tolerability by the investigator.
New abnormal findings were reported as Adverse Events (AE). Only Alanine aminotransferase normal under system organ class investigations was determined as an existing AE.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until up to 14 days after the last drug administration, up to 35 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin (Empa)</title>
          <description>Empagliflozin (Empa) 25 mg administered once daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Hydrochlorothiazide (HCT)</title>
          <description>Hydrochlorothiazide (HCT) 25 mg administered once daily for 4 days</description>
        </group>
        <group group_id="E3">
          <title>Torasemide (TOR)</title>
          <description>Torasemide (TOR) 5 mg administered once daily for 4 days</description>
        </group>
        <group group_id="E4">
          <title>Empa+ HCT</title>
          <description>Empagliflozin (Empa) 25 mg + Hydrochlorothiazide (HCT) 25 mg administered once daily for 5 days</description>
        </group>
        <group group_id="E5">
          <title>Empa + TOR</title>
          <description>Empagliflozin (Empa) 25 mg + Torasemide (TOR) 5 mg administered once daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information&quot;</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

